Marianne Graninger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marianne Graninger has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Hannes Vietzen
Center for Virology, Medical University of Vienna
5 shared publications - Elisabeth Puchhammer-Stöckl
Center for Virology, Medical University of Vienna, 1090 Vienna, Austria
4 shared publications Elisabeth Puchhammer‐Stöckl
Center for Virology Medical University of Vienna Vienna Austria
2 shared publications- Amy Tara Waldman
Division of Neurology, Children's Hospital of Philadelphia, PA
1 shared publication Barbara Kornek
Department of Neurology, Medical University of Vienna
1 shared publication- Bianca Weinstock-Guttman
Department of Neurology, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo Jacobs School of Medicine
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (40)
Impaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives
Multiple sclerosis (MS) is an autoinflammatory disease of the central nervous system (CNS). Epstein–Barr virus (EBV) encodes for EBNA-1 381-452 , which induces autoreactive immune responses against distinct CNS derived proteins (GlialCAM 370-389 , CRYAB 2-21 , MBP 205-224 , ANO2 135-154 ). Although EBV infection is considered essential for MS development, CNS-specific autoimmune responses may also be present in putatively EBV EBNA-1-seronegative patients, warranting further investigation. We studied 548 EBV EBNA-1 seropositive and 30 EBV EBNA-1 seronegative pediatric-onset MS (POMS) patients, along with 578 matched controls. CNS specific antibodies were significantly more prevalent in EBV EBNA-1 seropositive POMS patients (92.2%) than in EBV EBNA-1 seropositive controls (56.3%, P < 0.0001). However, high CNS specific antibody levels were also found in 56.6% of EBV EBNA-1 seronegative POMS patients and 17.4% of EBV EBNA-1 seronegative controls. These findings suggest that while EBV infection amplifies CNS specific autoimmune responses, high-level CNS autoreactive autoimmune responses can also occur independently of EBV EBNA-1. We further evaluated why only some individuals with high-level CNS autoreactive antibody titers develop MS. Mechanistically, we demonstrate that autoreactive immune responses are effectively controlled by NKG2C + and NKG2D + natural killer (NK) cells. These findings indicate that CNS-specific autoimmunity and impaired NK cell regulation, rather than EBV alone, are central to MS risk.
- 1 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (40)
Open AccessImpaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives
Multiple sclerosis (MS) is an autoinflammatory disease of the central nervous system (CNS). Epstein–Barr virus (EBV) encodes for EBNA-1 381-452 , which induces autoreactive immune responses against distinct CNS derived proteins (GlialCAM 370-389 , CRYAB 2-21 , MBP 205-224 , ANO2 135-154 ). Although EBV infection is considered essential for MS development, CNS-specific autoimmune responses may also be present in putatively EBV EBNA-1-seronegative patients, warranting further investigation. We studied 548 EBV EBNA-1 seropositive and 30 EBV EBNA-1 seronegative pediatric-onset MS (POMS) patients, along with 578 matched controls. CNS specific antibodies were significantly more prevalent in EBV EBNA-1 seropositive POMS patients (92.2%) than in EBV EBNA-1 seropositive controls (56.3%, P < 0.0001). However, high CNS specific antibody levels were also found in 56.6% of EBV EBNA-1 seronegative POMS patients and 17.4% of EBV EBNA-1 seronegative controls. These findings suggest that while EBV infection amplifies CNS specific autoimmune responses, high-level CNS autoreactive autoimmune responses can also occur independently of EBV EBNA-1. We further evaluated why only some individuals with high-level CNS autoreactive antibody titers develop MS. Mechanistically, we demonstrate that autoreactive immune responses are effectively controlled by NKG2C + and NKG2D + natural killer (NK) cells. These findings indicate that CNS-specific autoimmunity and impaired NK cell regulation, rather than EBV alone, are central to MS risk.
- Open Access
- 23 December 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (12) , e0086925
Herpesvirus-host interactions in neurological diseases: the immunogenetic role of HLA-E
Human herpesviruses (HHVs) comprise nine pathogenic members, including herpes simplex virus 1, herpes simplex virus 2, varicella-zoster virus, Epstein–Barr virus, human cytomegalovirus, human herpesvirus 6A/B, human herpesvirus 7, and Kaposi’s sarcoma-associated herpesvirus. Clinical manifestations of HHV infection can range from asymptomatic cases to a broad spectrum of neurological complications, spanning from acute conditions such as encephalitis to chronic disorders including Alzheimer’s disease and multiple sclerosis. By establishing latency and undergoing repeated reactivation, HHVs maintain lifelong interactions with the human immune system and shape host immune responses, exerting considerable impact on nervous system homeostasis. Individual susceptibility to, and outcomes of, HHV-associated neurological disorders depend on multiple factors, including the infecting HHV strain and host genetics. Recent evidence highlights the pivotal role of the human leukocyte antigen E (HLA-E) pathway—a non-classical major histocompatibility complex class I molecule with immunomodulatory functions—in regulating virus–host interactions. Since some HHVs manipulate HLA-E to evade immune recognition, individual variability in this axis may influence neurological outcomes. In this review, we summarize and discuss current knowledge of the role of HLA-E in herpesvirus-associated neurological diseases.
- 23 December 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (12) , e0086925
Open AccessHerpesvirus-host interactions in neurological diseases: the immunogenetic role of HLA-E
Human herpesviruses (HHVs) comprise nine pathogenic members, including herpes simplex virus 1, herpes simplex virus 2, varicella-zoster virus, Epstein–Barr virus, human cytomegalovirus, human herpesvirus 6A/B, human herpesvirus 7, and Kaposi’s sarcoma-associated herpesvirus. Clinical manifestations of HHV infection can range from asymptomatic cases to a broad spectrum of neurological complications, spanning from acute conditions such as encephalitis to chronic disorders including Alzheimer’s disease and multiple sclerosis. By establishing latency and undergoing repeated reactivation, HHVs maintain lifelong interactions with the human immune system and shape host immune responses, exerting considerable impact on nervous system homeostasis. Individual susceptibility to, and outcomes of, HHV-associated neurological disorders depend on multiple factors, including the infecting HHV strain and host genetics. Recent evidence highlights the pivotal role of the human leukocyte antigen E (HLA-E) pathway—a non-classical major histocompatibility complex class I molecule with immunomodulatory functions—in regulating virus–host interactions. Since some HHVs manipulate HLA-E to evade immune recognition, individual variability in this axis may influence neurological outcomes. In this review, we summarize and discuss current knowledge of the role of HLA-E in herpesvirus-associated neurological diseases.
- Open Access
- 21 October 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (10) , e70667
Distinct NK Cell Genetic Variants Are Associated With HSV‐2 Versus VZV Infection of the CNS
Human alphaherpesvirus infections may cause life‐threatening CNS disease. As NK cell responses are crucial for herpesvirus control, we assessed if specific human genetic variants with influence on host NK cell functions are associated with HSV‐2 or VZV CNS disease development. We included patients with confirmed CNS disease due to HSV‐2 ( n = 25) and VZV infection ( n = 39), and compared them to 400 population controls. The NK cell‐related human genetic variants HLA‐E * 0101/0103 , rs9916629 C/T, NKG2C wt/del, FcγRIIIa 158‐F/V were assessed in all cohorts. HLA‐E‐binding peptide sequences were assessed in the HSV‐2 and VZV reference sequences by NCBI BLAST and peptide prediction. In patients with HSV‐2‐related CNS disease, we observed a significantly increased frequency of the rs9916629 CC variant (32%) and the NKG2C del/del genotype (12%) compared to controls (8% and 1%; p = < 0.0001 and p = 0.0006, respectively), and these variants were identified as independent risk factors for HSV‐2 CNS disease. In contrast, VZV CNS patients showed a higher prevalence of the FcγRIIIa 158‐F/F variant (59%) than controls (34%; p = 0.006). Our results indicate that distinct NK cell pathways are affected in HSV‐2 and VZV CNS disease, respectively, and hint towards differences in genetic predispositions to HSV‐2 versus VZV CNS infection.
- 21 October 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (10) , e70667
Open AccessDistinct NK Cell Genetic Variants Are Associated With HSV‐2 Versus VZV Infection of the CNS
Human alphaherpesvirus infections may cause life‐threatening CNS disease. As NK cell responses are crucial for herpesvirus control, we assessed if specific human genetic variants with influence on host NK cell functions are associated with HSV‐2 or VZV CNS disease development. We included patients with confirmed CNS disease due to HSV‐2 ( n = 25) and VZV infection ( n = 39), and compared them to 400 population controls. The NK cell‐related human genetic variants HLA‐E * 0101/0103 , rs9916629 C/T, NKG2C wt/del, FcγRIIIa 158‐F/V were assessed in all cohorts. HLA‐E‐binding peptide sequences were assessed in the HSV‐2 and VZV reference sequences by NCBI BLAST and peptide prediction. In patients with HSV‐2‐related CNS disease, we observed a significantly increased frequency of the rs9916629 CC variant (32%) and the NKG2C del/del genotype (12%) compared to controls (8% and 1%; p = < 0.0001 and p = 0.0006, respectively), and these variants were identified as independent risk factors for HSV‐2 CNS disease. In contrast, VZV CNS patients showed a higher prevalence of the FcγRIIIa 158‐F/F variant (59%) than controls (34%; p = 0.006). Our results indicate that distinct NK cell pathways are affected in HSV‐2 and VZV CNS disease, respectively, and hint towards differences in genetic predispositions to HSV‐2 versus VZV CNS infection.
- Open Access
- 29 November 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (12) , e70091
Association Between NK Cell Genetic Variants and the Development of Long COVID Associated‐ and Prepandemic Small Fiber Neuropathy
Long coronavirus disease 2019 (COVID) (LC) symptoms including pain and autonomic dysfunction are in some patients associated with small‐fiber neuropathy (SFN). The pathomechanisms underlying SFN are mostly unclear. Natural killer (NK) cells play a crucial role in immune regulation, viral clearance and nerve metabolism. The aim of this study was to identify associations between development of small‐fiber dysfunction dependent and independent of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, and human genetic markers associated with specific NK cell functions. The genetic markers assessed in all cohorts included: FCGR3A, IGHG1, HLA‐E, NKG2C, and rs9916629. Genotyping was performed using TaqMan assays, Sanger sequencing and touchdown polymerase chain reaction. We assessed human cytomegalovirus (HCMV) IgG serostatus in all participants, and screened for anti‐neuronal, anti‐glial and anti‐ganglioside autoantibodies in both patient cohorts. We included 50 LC patients with newly‐emerged symptoms of small‐fiber dysfunction after SARS‐CoV‐2 infection, 27 prepandemic SFN patients and 320 control persons. Markers associated with low NKG2C response, that is, deletion of the NKG2C gene and lack of prior HCMV infection (IgG seronegativity), occurred significantly more frequently in prepandemic SFN patients compared to LC patients and controls (p = 0.0109 and 0.0005, respectively). In conclusion, markers of impaired NKG2C pathways are associated with prepandemic SFN, but not with Long COVID‐associated small‐fiber dysfunction.
- 29 November 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (12) , e70091
Open AccessAssociation Between NK Cell Genetic Variants and the Development of Long COVID Associated‐ and Prepandemic Small Fiber Neuropathy
Long coronavirus disease 2019 (COVID) (LC) symptoms including pain and autonomic dysfunction are in some patients associated with small‐fiber neuropathy (SFN). The pathomechanisms underlying SFN are mostly unclear. Natural killer (NK) cells play a crucial role in immune regulation, viral clearance and nerve metabolism. The aim of this study was to identify associations between development of small‐fiber dysfunction dependent and independent of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, and human genetic markers associated with specific NK cell functions. The genetic markers assessed in all cohorts included: FCGR3A, IGHG1, HLA‐E, NKG2C, and rs9916629. Genotyping was performed using TaqMan assays, Sanger sequencing and touchdown polymerase chain reaction. We assessed human cytomegalovirus (HCMV) IgG serostatus in all participants, and screened for anti‐neuronal, anti‐glial and anti‐ganglioside autoantibodies in both patient cohorts. We included 50 LC patients with newly‐emerged symptoms of small‐fiber dysfunction after SARS‐CoV‐2 infection, 27 prepandemic SFN patients and 320 control persons. Markers associated with low NKG2C response, that is, deletion of the NKG2C gene and lack of prior HCMV infection (IgG seronegativity), occurred significantly more frequently in prepandemic SFN patients compared to LC patients and controls (p = 0.0109 and 0.0005, respectively). In conclusion, markers of impaired NKG2C pathways are associated with prepandemic SFN, but not with Long COVID‐associated small‐fiber dysfunction.
- Open Access
- 27 April 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (5) , e28759
Association between human genetic variants affecting the host NK cell response and the development of herpes simplex virus type 1 encephalitis
Herpes simplex virus encephalitis (HSE) is a rare complication of herpes simplex virus type 1 (HSV‐1) infection or reactivation. It is so far unclear why only few patients develop HSE. As natural killer (NK) cells provide an important defense against HSV‐1, we investigated whether there is an association between distinct human genetic variants associated with the host NK cell response and HSE. Forty‐nine adult patients with confirmed HSE and 247 matched controls were analyzed for the distribution of the following genotypes: CD16A (FcγRIIIA) V/F and IGHG1 G1m3/17, both influencing antibody‐dependent cellular cytotoxicity; HLA‐E*0101/*0103, associated with NK cell activation; and SLFN13 rs9916629C/T associated with NK cell response. Homozygous HLA‐E*0101:0101 and HLA‐E*0103:0103 variants as well as the rs9916629CC genotype were overrepresented in HSE patients compared to controls (p ≤ 0.001). Notably, cooccurrence of the homozygous HLA‐E*0101 and rs9916629CC genotypes was present in 19% of patients but totally absent in controls (p ≤ 0.0001). Distribution of CD16A and IGHG1 variants did not differ between patients and controls. Our data show that the rare combination of HLA‐E*0101:0101 and rs9916629CC is significantly associated with HSE. Possibly, these genetic variations could be useful as clinical markers predicting HSE prognosis and helping to adapt the treatment of HSE in the individual patient.
- 27 April 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (5) , e28759
Open AccessAssociation between human genetic variants affecting the host NK cell response and the development of herpes simplex virus type 1 encephalitis
Herpes simplex virus encephalitis (HSE) is a rare complication of herpes simplex virus type 1 (HSV‐1) infection or reactivation. It is so far unclear why only few patients develop HSE. As natural killer (NK) cells provide an important defense against HSV‐1, we investigated whether there is an association between distinct human genetic variants associated with the host NK cell response and HSE. Forty‐nine adult patients with confirmed HSE and 247 matched controls were analyzed for the distribution of the following genotypes: CD16A (FcγRIIIA) V/F and IGHG1 G1m3/17, both influencing antibody‐dependent cellular cytotoxicity; HLA‐E*0101/*0103, associated with NK cell activation; and SLFN13 rs9916629C/T associated with NK cell response. Homozygous HLA‐E*0101:0101 and HLA‐E*0103:0103 variants as well as the rs9916629CC genotype were overrepresented in HSE patients compared to controls (p ≤ 0.001). Notably, cooccurrence of the homozygous HLA‐E*0101 and rs9916629CC genotypes was present in 19% of patients but totally absent in controls (p ≤ 0.0001). Distribution of CD16A and IGHG1 variants did not differ between patients and controls. Our data show that the rare combination of HLA‐E*0101:0101 and rs9916629CC is significantly associated with HSE. Possibly, these genetic variations could be useful as clinical markers predicting HSE prognosis and helping to adapt the treatment of HSE in the individual patient.
- Open Access
- 14 February 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (1) , e0231422
Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference
While the measurement of neutralizing antibodies is considered a valuable tool in assessing protection against SARS-CoV-2, neutralization tests employ live-virus isolates and cell culture, requiring advanced laboratory biosafety levels. Including a large sample panel (over 700 samples), this study provides adapted cutoff values calculated for seven commercial immunoassays (including four surrogate neutralization assays and a protein-based microarray) that robustly correlate with specific titers of neutralizing antibodies.
- 14 February 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (1) , e0231422
Open AccessComprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference
While the measurement of neutralizing antibodies is considered a valuable tool in assessing protection against SARS-CoV-2, neutralization tests employ live-virus isolates and cell culture, requiring advanced laboratory biosafety levels. Including a large sample panel (over 700 samples), this study provides adapted cutoff values calculated for seven commercial immunoassays (including four surrogate neutralization assays and a protein-based microarray) that robustly correlate with specific titers of neutralizing antibodies.
- Open Access
Association between Epstein‐Barr‐Virus reactivation and development of Long‐COVID fatigue